| budesonide inhalation suspension / Generic mfg. |
2019-002849-38: A clinical study to assess the safety, systemic exposure and efficacy of a liquid for inhalation of budesonide (AQ001S) to treat asthma. étude de la sécurité, de l’exposition systémique et de l’efficacité d’un liquide pour inhalation de budésonide dans le traitement de l’asthme |
|
|
| Not yet recruiting | 2/3 | 24 | Europe | Budesonide inhalation solution 0.125 mg/ml, Nebbud 0.25 mg/2 ml, AQ001S 0.125 mg/ml, Inhalation solution, Nebbud 0.25 mg/2 ml zawiesina do nebulizacji | Aquilon Pharmaceuticals, Walloon Region (SPW-EER) | asthma, asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2006-004035-30: A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide InhalationSolution (CBIS) Delivered via eFlow® Nebuliser and Conventional BudesonideInhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® JetNebuliser in Children with Asthma |
|
|
| Ongoing | 2 | 18 | Europe | Captisol-Enabled Budesonide, Pulmicort 250 Respules, CBIS, Pulmicort 250 Respules, Pulmicort 250 Respules | Verus Pharmaceuticals Inc | Asthma | | | | |
BOREAS, NCT04933383: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics |
|
|
| Completed | 1/2 | 23 | Europe | AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml | Aquilon Pharmaceuticals S.A. | Asthma | 12/22 | 01/23 | | |
2006-004045-42: Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort Respules, CBIS, Pulmicort Respules, Pulmicort Respules | Verus Pharmaceuticals Inc | Asthma | | | | |
2006-003801-21: A Randomised, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® Jet Nebuliser in Children with Mild-to-Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort 250 Repsules, CBIS, Pulmicort 250 Repsules, Pulmicort 250 Repsules | Verus Pharmaceuticals Inc | Asthma | | | | |
